Whole Woman's Health Of Charlottesville

CLIA Laboratory Citation Details

2
Total Citations
8
Total Deficiencyies
7
Unique D-Tags
CMS Certification Number 49D2038942
Address 2321 Commonwealth Drive, Charlottesville, VA, 22901
City Charlottesville
State VA
Zip Code22901
Phone(434) 973-4888

Citation History (2 surveys)

Survey - April 23, 2024

Survey Type: Standard

Survey Event ID: HDAH11

Deficiency Tags: D0000 D2007

Summary:

Summary Statement of Deficiencies D0000 An announced CLIA recertification survey was conducted at Whole Women's Health of Charlottesville on April 23, 2024 by the Virginia Department of Health's Office of Licensure and Certification. The laboratory was surveyed under 42 CFR part 493 CLIA Requirements. Specific deficiency cited is as follows: D2007 TESTING OF PROFICIENCY TESTING SAMPLES CFR(s): 493.801(b)(1) The samples must be examined or tested with the laboratory's regular patient workload by personnel who routinely perform the testing in the laboratory, using the laboratory's routine methods This STANDARD is not met as evidenced by: Based on review of the Centers for Medicare and Medicaid Services Laboratory Personnel form (CMS 209), proficiency testing (PT) records, and an interview, the laboratory failed to rotate PT among testing personnel (TP) performing patient immunohematology Rhesus (RhD) blood type testing for four (4) of five (5) events reviewed during the timeframe of June 10, 2022 to the date of the inspection on April 23, 2024. Findings include: 1. Review of the CMS 209 form revealed the laboratory director identified seven (7) testing personnel qualified/responsible for performing patient RhD testing during the review timeframe of 6/10/22 to 4/23/24. 2. Review of the laboratory's American Proficiency Institute (API) PT documentation, a total of 5 events (2022 Event 3, 2023 Events 1-3, 2024 Event 1), revealed that TP A signed attestations as performing the following PT events: 2022 API Immunohematology Event 3; 2023 API Immunohematology Event 1; 2023 API Immunohematology Event 2; 2023 API Immunohematology Event 3; TP A performed 4 of the 5 PT events reviewed (See Personnel Code Sheet). 3. An exit interview with the Associate Director of Clinical Services on 4/23/24 at 12 noon confirmed the above findings. Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 1 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - April 3, 2018

Survey Type: Standard

Survey Event ID: 7OQP11

Deficiency Tags: D0000 D2015 D5215 D5449 D6018 D6020

Summary:

Summary Statement of Deficiencies D0000 An announced CLIA recertification survey was conducted at Whole Women's Health of Charlottesville on April 3, 2018 by the Virginia Department of Health's Office of Licensure and Certification. The laboratory was surveyed under 42 CFR part 493 CLIA Requirements. Specific deficiencies cited are as follows: D2015 TESTING OF PROFICIENCY TESTING SAMPLES CFR(s): 493.801(b)(5)(6) (5) The laboratory must document the handling, preparation, processing, examination, and each step in the testing and reporting of results for all proficiency testing samples. The laboratory must maintain a copy of all records, including a copy of the proficiency testing program report forms used by the laboratory to record proficiency testing results including the attestation statement provided by the PT program, signed by the analyst and the laboratory director, documenting that proficiency testing samples were tested in the same manner as patient specimens, for a minimum of two years from the date of the proficiency testing event. (6) PT is required for only the test system, assay, or examination used as the primary method for patient testing during the PT event. This STANDARD is not met as evidenced by: Based on a review of the laboratory's proficiency testing (PT) documentation, and an interview, the laboratory failed to retain attestation statements signed by the laboratory director and testing personnel for three (3) of six (6) events reviewed. Findings include: 1. Review of the laboratory's 2016 American Academy of Family Physicians (AAFP) Blood Bank Testing Rh Factor PT documentation, and 2017 American Association of Bioanalysts (AAB), a total of six (6) events, revealed no signed attestation statements for: 2016 AAFP Event A, 2016 AAFP Event B, 2016 AAFP Event C. The inspector requested to review the attestation documentation. No documentation was available for review. 2. During the exit interview with the Laboratory Director, Clinic Manager, and Director of Special Projects at Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 4 -- approximately 4:30 PM, it was confirmed that the laboratory failed to retain copies of the AAFP attestation statements for the PT events outlined above in 2016. D5215 EVALUATION OF PROFICIENCY TESTING PERFORMANCE CFR(s): 493.1236(b)(2) The laboratory must verify the accuracy of any analyte, specialty or subspecialty assigned a proficiency testing score that does not reflect laboratory test performance (that is, when the proficiency testing program does not obtain the agreement required for scoring as specified in subpart I of this part, or the laboratory receives a zero score for nonparticipation, or late return or results). This STANDARD is not met as evidenced by: Based on a review of proficiency testing (PT) records and interviews, the laboratory failed to evaluate non-graded PT results for three (3) of fifteen (15) Blood Bank Testing Rh Factor challenges reviewed for calendar year 2016. Findings include: 1. Review of the laboratory's American Academy of Family Physicians (AAFP) PT documentation for 2016, a total of three (3) events and fifteen (15) challenges, revealed no evaluation or verification of accuracy for the non-graded responses for: 2016 Event C Blood Bank Testing Rh Factor - BB 11, BB 12, BB 13. The inspector requested to review evaluation documentation for the three (3) non-graded challenges listed above. No additional documentation was available for review. 2. In an interview with the Laboratory Director, Clinic Manager, and Director of Special Projects at approximately 4:30 PM, it was confirmed that the laboratory failed to evaluate the non-graded PT results for the event listed above. D5449 CONTROL PROCEDURES CFR(s): 493.1256(d)(3)(ii)(g) Unless CMS Approves a procedure, specified in Appendix C of the State Operations Manual (CMS Pub. 7), that provides equivalent quality testing, the laboratory must-- At least once a day patient specimens are assayed or examined perform the following for-- Each qualitative procedure, include a negative and positive control material; (g) The laboratory must document all control procedures performed. This STANDARD is not met as evidenced by: Based on a tour, review of the laboratory's test logs, quality assurance (QA) policy, and interviews, the laboratory failed to document quality control (QC) for Anti-D Rh tests on twenty (20) days of patient testing in the fifteen (15) months reviewed. Findings include: 1. During a tour of the laboratory testing area, the inspector noted the moderate complexity qualitative Eldoncard Rhesus Factor kits in use for RhD antigen detection. The inspector requested to see the quality control media used for the kits. The lab director stated "the QC is on order. We do not have any vials at this time". 2. Review of the laboratory's patient test logs from January 2016 to the date of the survey, April 3, 2018 revealed the following twenty (20) days with no QC documentation: 11/16/17, 12/13/17, 12/14/17, 12/20/17, 12/21/17, 01/03/18, 01/04/18, 01/10/18, 01/11/18, 01/18/18, 01/22/18, 01/23/18, 01/25/18, 01/30/18, 01/31/18, 02/01 /18, 02/05/18, 02/06/18, 02/07/18, and 02/12/18. The inspector requested to review the QC documentation on the dates of patient testing listed above. No documentation was available for review. 3. Review of the laboratory's QA policies revealed a QC protocol that stated: "Rh controls are to be documented daily. Results of all tests are -- 2 of 4 -- recorded on the daily log sheet with proper laboratory testing protocol that QC is verified". 4. During the exit interview with the Laboratory Director, Clinic Manager, and Director of Special Projects at approximately 4:30 PM, it was confirmed that the laboratory failed to document quality control (QC) for Anti-D Rh on twenty (20) days of patient testing in the fifteen (15) months reviewed. D6018 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1407(e)(4)(iii) The laboratory director is responsible for the overall operation and administration of the laboratory, including the employment of personnel who are competent to perform test procedures, and record and report test results promptly, accurate, and proficiently and for assuring compliance with the applicable regulations. (e) The laboratory director must-- (e)(4)(iii) Ensure that all proficiency testing reports received are reviewed by the appropriate staff to evaluate the laboratory's performance and to identify any problems that require

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access